1. Home
  2. SATL vs CTNM Comparison

SATL vs CTNM Comparison

Compare SATL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Satellogic Inc.

SATL

Satellogic Inc.

HOLD

Current Price

$4.66

Market Cap

529.2M

Sector

Technology

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$16.90

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SATL
CTNM
Founded
2010
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
529.2M
550.7M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
SATL
CTNM
Price
$4.66
$16.90
Analyst Decision
Strong Buy
Buy
Analyst Count
3
4
Target Price
$5.50
$19.00
AVG Volume (30 Days)
5.5M
540.4K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
85.94
0.46
EPS
N/A
N/A
Revenue
$17,707,000.00
N/A
Revenue This Year
$88.89
N/A
Revenue Next Year
$56.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
37.58
N/A
52 Week Low
$1.26
$8.60
52 Week High
$12.00
$17.51

Technical Indicators

Market Signals
Indicator
SATL
CTNM
Relative Strength Index (RSI) 41.79 57.09
Support Level $4.52 $13.65
Resistance Level $6.09 $17.04
Average True Range (ATR) 0.33 0.97
MACD -0.12 0.02
Stochastic Oscillator 2.13 72.87

Price Performance

Historical Comparison
SATL
CTNM

About SATL Satellogic Inc.

Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: